Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Annals of Hematology|October 18, 2023
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myelomaJames A Davis, Aswani Thurlapati, Erin Weeda, et al.Blood Cancer Journal|March 11, 2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myelomaRachel Dileo, Prerna Mewawalla, Kalaivani Babu, et al.Clinical Lymphoma, Myeloma & Leukemia|September 17, 2025
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World ExperienceAnas Zayad, Gray Magee, Razan Mansour, et al.European Journal of Haematology|January 16, 2026
Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter StudyRazan Mansour, Kimberly M Green, Chandler Graf, et al.Journal of Contaminant Hydrology|March 19, 2013
Persistence of uranium groundwater plumes: contrasting mechanisms at two DOE sites in the groundwater-river interaction zoneJohn M Zachara, Philip E Long, John Bargar, et al.Environmental Science & Technology|September 30, 2014
Speciation and reactivity of uranium products formed during in situ bioremediation in a shallow alluvial aquiferDaniel S Alessi, Juan S Lezama-Pacheco, Noémie Janot, et al.Transplantation and Cellular Therapy|December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World ExperienceDanai Dima, James A Davis, Nausheen Ahmed, et al.Blood Cancer Journal|May 31, 2024
Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell TherapyDanai Dima, Al-Ola Abdallah, James A Davis, et al.Transplantation and Cellular Therapy|June 13, 2024
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in MyelomaWilliam Wesson, Danai Dima, Nahid Suleman, et al.Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.Pageof 10